BRPI0414565A - composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato - Google Patents

composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato

Info

Publication number
BRPI0414565A
BRPI0414565A BRPI0414565-8A BRPI0414565A BRPI0414565A BR PI0414565 A BRPI0414565 A BR PI0414565A BR PI0414565 A BRPI0414565 A BR PI0414565A BR PI0414565 A BRPI0414565 A BR PI0414565A
Authority
BR
Brazil
Prior art keywords
methods
bisphosphonate
pharmaceutical compositions
alkylidene
vitamin
Prior art date
Application number
BRPI0414565-8A
Other languages
English (en)
Inventor
Andrew George Lee
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0414565A publication Critical patent/BRPI0414565A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS E MéTODOS QUE COMPREENDEM COMBINAçõES DE DERIVADOS DE 2-ALQUILIDENO-19-NOR-VITAMINA D E UM BISFOSFONATO". A presente invenção refere-se a composições farmacêuticas e métodos de tratamento compreendendo a administração a um doente em sua necessidade uma combinação de um derivado de 2-alquilideno-19-norvitamina D e um bisfosfonato. Particularmente, a presente invenção refere-se a composições farmacêuticas e métodos de tratamento compreendendo a administração a um paciente em sua necessidade de 2-metilideno-19-nor20(S)-1<244>,25-dihidroxivitamina D~ 3~ e um bisfosfonato.
BRPI0414565-8A 2003-09-19 2004-09-06 composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato BRPI0414565A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50400803P 2003-09-19 2003-09-19
PCT/IB2004/002935 WO2005027921A1 (en) 2003-09-19 2004-09-06 Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate

Publications (1)

Publication Number Publication Date
BRPI0414565A true BRPI0414565A (pt) 2006-11-07

Family

ID=34375430

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414565-8A BRPI0414565A (pt) 2003-09-19 2004-09-06 composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato

Country Status (16)

Country Link
US (1) US20050065117A1 (pt)
EP (1) EP1667691A1 (pt)
JP (1) JP2007505886A (pt)
KR (1) KR20060058134A (pt)
CN (1) CN1852719A (pt)
AU (1) AU2004273672A1 (pt)
BR (1) BRPI0414565A (pt)
CA (1) CA2539359A1 (pt)
IL (1) IL174216A0 (pt)
MX (1) MXPA06003063A (pt)
NO (1) NO20061245L (pt)
NZ (1) NZ545804A (pt)
RU (1) RU2326695C2 (pt)
TW (1) TW200524617A (pt)
WO (1) WO2005027921A1 (pt)
ZA (1) ZA200602270B (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US7122533B2 (en) * 1999-11-29 2006-10-17 The United States Of America As Represented By The Department Of Health And Human Services Cosalane compounds and methods for their use
US20080249068A1 (en) * 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
WO2006061683A1 (en) * 2004-12-09 2006-06-15 Pfizer Products Inc. 2-alkylidene-19-nor-vitamin d derivatives for the treatment of osteogenesis imperfecta
EP1798236A1 (en) * 2005-12-13 2007-06-20 EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. Process for the preparation of 3-pyridyl-1-hydroxyethylidene-1,1- biphosphonic acid and hydrated forms thereof
ES2426445T3 (es) * 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
EP2136814A4 (en) * 2007-03-21 2012-05-30 Univ Duke MEDICAL KITS AND FORMULATIONS FOR PREVENTING, TREATING OR REDUCING SECONDARY FRACTURES FROM A PREVIOUS FRACTURE
KR100844256B1 (ko) 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
EA201001097A1 (ru) * 2008-03-18 2011-02-28 Александр Владимирович ДИКОВСКИЙ Фармацевтическая композиция для профилактики и лечения резорбции костной ткани различной этиологии
WO2009137080A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of gnrh related compounds and processes of preparation
TR200900880A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik bileşimler.
TR200900878A2 (tr) 2009-02-05 2010-08-23 Bi̇lgi̇ç Mahmut Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
US20100215743A1 (en) * 2009-02-25 2010-08-26 Leonard Thomas W Composition and drug delivery of bisphosphonates
EP2459176B1 (en) 2009-07-31 2017-09-27 Grünenthal GmbH Crystallization method and bioavailability
DK2473172T3 (en) 2009-09-01 2015-06-15 Univ Duke BISPHOSPHONATSAMMENSÆTNINGER and Methods for treating congestive heart failure
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
US9340565B2 (en) 2010-11-24 2016-05-17 Thar Pharmaceuticals, Inc. Crystalline forms
US8802114B2 (en) 2011-01-07 2014-08-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
CA2856030A1 (en) 2011-11-16 2013-05-23 Duke University Bisphosphonate compositions and methods for treating and/or reducing cardiac dysfunction
US9012432B2 (en) * 2013-03-08 2015-04-21 Levolta Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
US8859530B2 (en) 2013-03-08 2014-10-14 Voltarra Pharmaceuticals, Inc. Co-administration of steroids and zoledronic acid to prevent and treat osteoarthritis
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
IT201700031017A1 (it) * 2017-03-21 2018-09-21 Bioenx S R L Composizioni utili per il trattamento dell'alopecia androgenica comprendenti acido etidronico
AU2017422200B2 (en) 2017-07-05 2022-11-24 E.P.O.S Iasis Research And Development Limited Multifunctional conjugates
CN107441101A (zh) * 2017-09-04 2017-12-08 杭州旦承医药科技有限公司 伊班膦酸钠的用途及粉雾剂和制备方法
CN107550919A (zh) * 2017-09-04 2018-01-09 杭州旦承医药科技有限公司 唑来膦酸的用途及粉雾剂和制备方法
MX2021014028A (es) * 2019-05-17 2022-02-21 Univ Pennsylvania Métodos y composiciones para tratar obesidad y/o trastornos de la piel.
GB202016614D0 (en) 2020-10-20 2020-12-02 King S College London Compounds
WO2023177283A1 (en) * 2022-03-14 2023-09-21 Erasmus University Medical Center Rotterdam A combination therapy for bone loss and/or muscle loss.

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3683080A (en) * 1970-08-28 1972-08-08 Procter & Gamble Compositions for inhibiting anomalous deposition and mobilization of calcium phosphate in animal tissue
US4134969A (en) * 1974-02-04 1979-01-16 Henkel Kommanditgesellschaft Auf Aktien (Henkel Kgaa) Method of treatment of calcium disorders using aminoalkane-diphosphonic acids
IT1194748B (it) * 1981-02-12 1988-09-28 Gentili Ist Spa Composizioni farmaceutiche per il trattamento di osteopatie
IT1201087B (it) * 1982-04-15 1989-01-27 Gentili Ist Spa Bifosfonati farmacologicamente attivi,procedimento per la loro preparazione e relative composizioni farmaceutiche
FR2531088B1 (fr) * 1982-07-29 1987-08-28 Sanofi Sa Produits anti-inflammatoires derives de l'acide methylenediphosphonique et leur procede de preparation
IL77243A (en) * 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
US4761406A (en) * 1985-06-06 1988-08-02 The Procter & Gamble Company Regimen for treating osteoporosis
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3776880D1 (de) * 1986-11-21 1992-04-02 Ciba Geigy Ag Neue substituierte alkandiphosphonsaeuren.
CA1339805C (en) * 1988-01-20 1998-04-07 Yasuo Isomura (cycloalkylamino)methylenebis(phosphonic acid) and medicines containing the same as an active
FR2629716B1 (fr) * 1988-04-07 1991-07-19 Sanofi Sa Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique
US4922007A (en) * 1989-06-09 1990-05-01 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or salts thereof
US5019651A (en) * 1990-06-20 1991-05-28 Merck & Co., Inc. Process for preparing 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid (ABP) or salts thereof
US5086191A (en) * 1991-05-28 1992-02-04 Wisconsin Alumni Research Foundation Intermediates for the synthesis of 19-nor vitamin D compounds
US6096342A (en) * 1997-03-12 2000-08-01 The Procter & Gamble Company Dosage forms of risedronate
FR2694558B1 (fr) * 1992-08-05 1994-10-28 Sanofi Elf Monohydrate du sel disodique de l'acide 4-chlorophénylthiométhylène bisphosphonique, sa préparation, les compositions pharmaceutiques en contenant.
GB9220439D0 (en) * 1992-09-28 1992-11-11 Leo Pharm Prod Ltd Chemical compounds
DE69400495T2 (de) * 1993-04-05 1997-04-30 Wisconsin Alumni Res Found 19-Nor-vitamin-D3-Verbindung mit einem Substituent an die 2. Stelle
TW257765B (pt) * 1993-08-25 1995-09-21 Merck & Co Inc
US5510517A (en) * 1993-08-25 1996-04-23 Merck & Co., Inc. Process for producing N-amino-1-hydroxy-alkylidene-1,1-bisphosphonic acids
US5656288A (en) * 1995-06-08 1997-08-12 Sanofi Winthrop, Inc. Stable pharmaceutical compositions containing tiludronate hydrates and process for producing the pharmaceutical compositions
US6316642B1 (en) * 1997-03-17 2001-11-13 Wisconsin Alumni Research Foundation 26,27-Homologated-20-EPI-2alkyl-19-nor-vitamin D compounds
US5843928A (en) * 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
ES2226128T3 (es) * 1997-06-11 2005-03-16 THE PROCTER &amp; GAMBLE COMPANY Comprimido revestido con una pelicula para una seguridad del tracto gastrointestinal superior mejorada.
PT1175904E (pt) * 1997-07-22 2007-04-30 Merck & Co Inc Alendronato para utilização no tratamento da osteoporose
US6432932B1 (en) * 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6015801A (en) * 1997-07-22 2000-01-18 Merck & Co., Inc. Method for inhibiting bone resorption
US5843923A (en) * 1998-05-22 1998-12-01 Jame Fine Chemicals, Inc. Glucosamine sulfate potassium chloride and process of preparation thereof
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
GB9907908D0 (en) * 1999-04-07 1999-06-02 Bataille Regis Organic compounds
DE19935771A1 (de) * 1999-07-23 2001-02-01 Schering Ag Neue Vitamin D-Derivate mit cyclischen Substrukturen in den Seitenketten, Verfahren und Zwischenprodukte zu ihrer Herstellung und die Verwendung zur Herstellung von Arzneimitteln
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
KR100317935B1 (ko) * 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
AU2002244520B2 (en) * 2001-04-03 2007-05-24 The Royal Alexandra Hospital For Children A drug for use in bone grafting
CZ20032950A3 (cs) * 2001-05-02 2004-06-16 Novartis Ag Léčiva s obsahem bisfosfonátů pro léčení karcinomu prostaty
US6835723B2 (en) * 2001-12-13 2004-12-28 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-1α-hydroxy-bis-homo-pregnacalciferol in crystalline form
US6894037B2 (en) * 2003-07-03 2005-05-17 Wisconsin Alumni Research Foundation 2-methylene-19-nor-20(S)-25-methyl-1α-hydroxycalciferol and its uses

Also Published As

Publication number Publication date
JP2007505886A (ja) 2007-03-15
IL174216A0 (en) 2006-08-01
NZ545804A (en) 2009-09-25
ZA200602270B (en) 2007-09-26
AU2004273672A1 (en) 2005-03-31
CN1852719A (zh) 2006-10-25
US20050065117A1 (en) 2005-03-24
EP1667691A1 (en) 2006-06-14
MXPA06003063A (es) 2006-05-31
RU2326695C2 (ru) 2008-06-20
TW200524617A (en) 2005-08-01
KR20060058134A (ko) 2006-05-29
CA2539359A1 (en) 2005-03-31
RU2006108550A (ru) 2007-09-27
WO2005027921A1 (en) 2005-03-31
NO20061245L (no) 2006-05-31

Similar Documents

Publication Publication Date Title
BRPI0414565A (pt) composições farmacêuticas e métodos que compreendem combinações de derivados de 2-alquilideno-19-nor-vitamina d e um bisfosfonato
BR0214343A (pt) Inibidores de 11 - beta - hidroxi esteróide desidrogenase tipo 1
BR0316906A (pt) administração do capsaicinoides
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
EA200800056A1 (ru) Каннабиноидный активный фармацевтический ингредиент для лекарственных форм
TW200612987A (en) Combination treatment for non-hematologic malignancies
PL1819227T3 (pl) Preparat farmaceutyczny decytabiny
HUS1500018I1 (hu) A Bruton-féle tirozin-kináz inhibitorai
SE0001899D0 (sv) New compounds
BRPI0515316A (pt) compostos de imidazoquinolina
BR0313148A (pt) Formulações de liberação controlada compreendendo lamotrigina
BRPI0515645A (pt) métodos terapêuticos, composições, compostos e usos de compostos
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
NO20062355L (no) Sammensetninger for behandling av sykdom i munnhulen og ovre andedrettssystem
BRPI0518659A2 (pt) composiÇço oral, e, mÉtodos de usar uma composiÇço oral para remover placa dental e/ou inibir a deposiÇço de placa dental dentro da cavidade oral e para pelo menos um dentre remover placa dental e inibir deposiÇço de placa dental dentro da cavidade oral de um indivÍduo humano ou outro animal
DE60218193D1 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
BRPI0507657A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para tratar um distúrbio, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BRPI0515209A (pt) compostos, composição cosmética, usos de uma composição e composição farmacêutica
BRPI0414518A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e hormÈnio paratireoidiano
BRPI0408848A (pt) formulações orais de cladribine
BRPI0410623A (pt) composto, processo para preparação de um composto, composição farmacêutica, e, utilização de um composto
BRPI0414448A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.